PART I . OVERVIEW AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates. While we historically used our p...
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001703057-26-000012 | EDGAR | 92K words |
| 2025-02-27 | 2024-12-31 | 0001628280-25-008689 | EDGAR | — |
| 2024-02-20 | 2023-12-31 | 0001703057-24-000019 | EDGAR | — |
| 2023-02-21 | 2022-12-31 | 0001564590-23-002128 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0001564590-22-007077 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001564590-21-016713 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001703057-25-000025 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0001703057-25-000011 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023836 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0001628280-24-045026 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035248 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001628280-24-021159 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001703057-23-000040 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001703057-23-000022 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001703057-23-000008 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001564590-22-037060 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028784 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019294 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001703057-26-000010 | EDGAR | 3K words |
| 2026-01-14 | 0001703057-26-000003 | EDGAR | — |
| 2025-12-18 | 0001703057-25-000034 | EDGAR | — |
| 2025-11-28 | 0001703057-25-000032 | EDGAR | — |
| 2025-11-12 | 0001703057-25-000029 | EDGAR | — |
| 2025-11-06 | 0001703057-25-000024 | EDGAR | — |
| 2025-09-10 | 0001703057-25-000018 | EDGAR | — |
| 2025-08-07 | 0001628280-25-038927 | EDGAR | — |
| 2025-06-13 | 0001628280-25-031219 | EDGAR | — |
| 2025-05-30 | 0001628280-25-028529 | EDGAR | — |
85 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001703057 |
| Ticker | ABCL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Website | https://www.abcellera.com |
| Listed | 2020-12-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report